INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc.

Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sunesis Pharmaceuticals, Inc. (“Sunesis” or the “Company”) (Nasdaq: SNSS).

If you purchased or otherwise acquired Sunesis shares, and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The investigation focuses on whether Sunesis and certain of its officers and/or directors violated federal securities laws. On May 2, 2017, the Company announced that it will withdraw its European Marketing Authorization Application for vosaroxin, its proposed treatment for relapsed/refractory AML. Sunesis stated that its decision followed recent interactions with the European Medicine Agency’s Committee for Medicinal Products for Human Use, in which it learned that the committee was likely to adopt a negative opinion in its evaluation of the product. When this news was announced, shares of Sunesis dropped in value.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170502006987/en/